Table 1.
Clinical and epidemiological characteristics.
Table 2.
Changes in bioimpedance based on length of hospitalization.
Table 3.
Changes in bioimpedance by sex.
Fig 1.
Weight loss survival curve by sex during inpatient treatment.
Medians to reach 20% of weight loss: Female 5.7 months (95%CI: 5.6–5.8 months); Male 5.3 months (95%CI: 5.2–5.4 months); Log rank (Mantel-Cox test): 72.7; p<0.001.
Fig 2.
Fat mass loss survival curve by sex during inpatient treatment.
Medians to reach 35% of fat mass loss: Female 5.8 months (95%CI: 5.7–5.8 months); Male 4.9 months (95%CI: 4.8–5.0 months); Log rank (Mantel-Cox test): 249.6; p<0.001.
Table 4.
Changes in bioimpedance by age.
Table 5.
Changes* in glycide, lipid, and hepatic parameters.
Fig 3.
Weight loss survival curve by age during inpatient treatment.
Medians to reach 20% of weight loss: Non-elderly patients 5.5 months (95%CI: 5.4–5.6 months); Elderly patients 5.8 months (95%CI: 5.7–5.8 months); Log rank (Mantel-Cox test): 23.2; p<0.001.
Fig 4.
Fat mass loss survival curve by age during inpatient treatment.
Medians to reach 35% of fat mass loss: Non-elderly patients 5.4 months (95%CI: 5.4–5.5 months); Elderly patients 5.7 months (95%CI: 5.6–5.8 months); Log rank (Mantel-Cox test): 29.6; p<0.001.
Table 6.
Factor associated with body fat mass loss* in both periods of inpatient treatment.